Literature DB >> 30806190

A Review of Integrated Care for Concurrent Disorders: Cost Effectiveness and Clinical Outcomes.

Venu Karapareddy1,2.   

Abstract

Objective: The recognition of concurrent disorders (combined mental health and substance use disorders) has increased substantially over the last three decades, leading to greater numbers of people with these diagnoses and a subsequent greater financial burden on the health care system, yet establishing effective modes of management remains a challenge. Further, there is little evidence on which to base recommendations for a particular mode of health service delivery. This paper will further summarize the existing treatment models for a comprehensive overview. The objectives of this study are to determine whether existing service models are effective in treating combined mental health and substance use disorders and to examine whether an integrated model of service delivery should be recommended to policy makers. The following two research questions are the focus of this paper: (1) Are the existing service models effective at treating mental health and substance use disorders? (2) How are existing service models effective at treating mental health and substance use disorders?
Methods: We used various databases to systematically review the effectiveness of service delivery models to treat concurrent disorders. Models were considered effective if they are found to be cost-effective and significantly improve clinical and social outcomes.
Results: This systematic review revealed that integrated models of care are more effective than conventional, nonintegrated models. Integrated models demonstrated superiority to standard care models through reductions in substance use disorders and improvement of mental health in patients who had diagnoses of concurrent disorders. Our meta-analysis revealed similar findings, indicating that the integrated model is more cost-effective than standard care. Conclusions: Given the limited number of studies in relation to service delivery for concurrent disorders, it is too early to make a strong evidence-based recommendation to policy makers and service providers as to the superiority of one approach over the others. However, the available evidence suggests that integrated care models for concurrent disorders are the most effective models for patient care. More research is needed, especially around the translation of research findings to policy development and, vice versa, around the translation from the policy level to the patients' level.

Entities:  

Keywords:  Concurrent disorders service delivery; concurrent disorders treatment; cost effectiveness; integrated treatment

Mesh:

Year:  2019        PMID: 30806190     DOI: 10.1080/15504263.2018.1518553

Source DB:  PubMed          Journal:  J Dual Diagn        ISSN: 1550-4271


  13 in total

1.  Improving Medication Access within Integrated Treatment for Individuals with Co-Occurring Disorders in Substance Use Treatment Agencies.

Authors:  James H Ford; Arveen Kaur; Deepika Rao; Aaron Gilson; Daniel M Bolt; Helene Chokron Garneau; Lisa Saldana; Mark P McGovern
Journal:  Implement Res Pract       Date:  2021-09-17

2.  Co-Occurring Obsessive-Compulsive Disorder and Compulsive Sexual Behavior: Clinical Features and Psychiatric Comorbidities.

Authors:  Lindsey A Snaychuk; Ygor A Ferrão; Leonardo F Fontenelle; Euripedes C Miguel; Maria A de Mathis; Marco D T Scanavino; Hyoun S Kim
Journal:  Arch Sex Behav       Date:  2022-09-06

3.  Wait No Longer: Reducing Medication Wait-Times for Individuals with Co-Occurring Disorders.

Authors:  James H Ford; Deepika Rao; Aaron Gilson; Arveen Kaur; Helene Chokron Garneau; Lisa Saldana; Mark P McGovern
Journal:  J Dual Diagn       Date:  2022-04-07

4.  Sustainment of Integrated Care in Addiction Treatment Settings: Primary Outcomes From a Cluster-Randomized Controlled Trial.

Authors:  Helene Chokron Garneau; Mehret T Assefa; Booil Jo; James H Ford; Lisa Saldana; Mark P McGovern
Journal:  Psychiatr Serv       Date:  2021-08-04       Impact factor: 3.084

5.  Posttraumatic Stress Disorder Symptomatology and Substance Use in an Outpatient Concurrent Disorders Sample.

Authors:  Herry Patel; Katherine Holshausen; Assaf Oshri; Krysta Andrews; Stephanie Penta; Holly Raymond; Margaret McKinnon; Jennifer Brasch; James MacKillop; Michael Amlung
Journal:  Can J Psychiatry       Date:  2021-04-20       Impact factor: 4.356

6.  EPA guidance on the quality of mental health services: A systematic meta-review and update of recommendations focusing on care coordination.

Authors:  W Gaebel; A Kerst; B Janssen; T Becker; M Musalek; W Rössler; M Ruggeri; G Thornicroft; J Zielasek; J Stricker
Journal:  Eur Psychiatry       Date:  2020-07-24       Impact factor: 5.361

7.  Changes in Loss Sensitivity During Treatment in Concurrent Disorders Inpatients: A Computational Model Approach to Assessing Risky Decision-Making.

Authors:  Stefanie Todesco; Thomas Chao; Laura Schmid; Karina A Thiessen; Christian G Schütz
Journal:  Front Psychiatry       Date:  2022-01-28       Impact factor: 4.157

8.  The Clinical Utility of Food Addiction: Characteristics and Psychosocial Impairments in a Treatment-Seeking Sample.

Authors:  Edgar Oliveira; Hyoun S Kim; Emilie Lacroix; Mária de Fátima Vasques; Cristiane Ruiz Durante; Daniela Pereira; Janice Rico Cabral; Paula Sanches Bernstein; Ximena Garcia; Emma V Ritchie; Hermano Tavares
Journal:  Nutrients       Date:  2020-11-04       Impact factor: 5.717

Review 9.  Concurrent Disorder Management Guidelines. Systematic Review.

Authors:  Syune Hakobyan; Sara Vazirian; Stephen Lee-Cheong; Michael Krausz; William G Honer; Christian G Schutz
Journal:  J Clin Med       Date:  2020-07-28       Impact factor: 4.241

Review 10.  Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment.

Authors:  Jessica L Taylor; Samantha Johnson; Ricardo Cruz; Jessica R Gray; Davida Schiff; Sarah M Bagley
Journal:  J Gen Intern Med       Date:  2021-06-22       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.